本发明是一种化合物,其化学式为
1
其中
R
1
是卤素或较低的烷基;
R
2
是氢、较低的烷基、环烷基、—(CH
2
)
m
-苯基,其中苯环可能被较低的烷氧基取代,或者是—(CH
2
)
m
-吲哚基;
R
3
是—C(O)O-较低的烷基、—C(O)OH,或者是一个五元杂环芳基,这些环可能被较低的烷基或环烷基取代;
n为0、1或2;
m为0、1或2;
或其药学上可接受的酸盐。化合物I显示出对GALA A &agr;5受体结合位点的高亲和力和选择性。
本发明是一种化合物,其化学式为
1
其中
R
1
是卤素或较低的烷基;
R
2
是氢、较低的烷基、环烷基、—(CH
2
)
m
-苯基,其中苯环可能被较低的烷氧基取代,或者是—(CH
2
)
m
-吲哚基;
R
3
是—C(O)O-较低的烷基、—C(O)OH,或者是一个五元杂环芳基,这些环可能被较低的烷基或环烷基取代;
n为0、1或2;
m为0、1或2;
或其药学上可接受的酸盐。化合物I显示出对GALA A &agr;5受体结合位点的高亲和力和选择性。
The present invention is a compound of formula
wherein
R1 is halogen or lower alkyl;
R2 is hydrogen, lower alkyl, cycloalkyl, —(CH2)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH2)m-indolyl;
R3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A &agr;5 receptor binding sites.
本发明涉及一种化合物,其化学式为:其中,R1为卤素或低碳基;R2为氢,低碳基,环烷基,-(CH2)m-苯基,其中苯环可以被低碳氧基取代,或者为-(CH2)m-吲哚基;R3为-C(O)O-低碳基,-C(O)OH,或者为五元杂环芳基,该环可以被低碳基或环烷基取代;n为0、1或2;m为0、1或2;或其药学上可接受的酸加合物盐。化合物I显示出对GALA A &agr;5受体结合位点具有高亲和力和选择性。
IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS
申请人:F. Hoffmann-La Roche AG
公开号:EP1399448B1
公开(公告)日:2004-12-01
US6686352B2
申请人:——
公开号:US6686352B2
公开(公告)日:2004-02-03
[EN] IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS<br/>[FR] DERIVES D'IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE EN TANT QUE MODULATEURS DU RECEPTEUR GABA A
申请人:HOFFMANN LA ROCHE
公开号:WO2002094834A1
公开(公告)日:2002-11-28
The present invention relates to compounds of formula (I) wherein R1 is halogen or lower alkyl; R2 is hydrogen, lower alkyl, cycloalkyl, -(CH¿2?)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is (CH2)m-indolyl; R?3¿ is C(O)O-lower alkyl, -C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2 ; m is 0, 1 or 2 ; and their pharmaceutically acceptable acid addition salts. It has been found that this class of compounds show high affinity and selectivity for GABA A α5 receptor binding sites and might be useful for the treatment of cognitive enhancer or of cognitive disorders like Alzheimer's disease.
The present invention is a compound of formula
1
wherein
R
1
is halogen or lower alkyl;
R
2
is hydrogen, lower alkyl, cycloalkyl, —(CH
2
)
m
-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH
2
)
m
-indolyl;
R
3
is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A &agr;5 receptor binding sites.
本发明是一种化合物,其化学式为
1
其中
R
1
是卤素或较低的烷基;
R
2
是氢、较低的烷基、环烷基、—(CH
2
)
m
-苯基,其中苯环可能被较低的烷氧基取代,或者是—(CH
2
)
m
-吲哚基;
R
3
是—C(O)O-较低的烷基、—C(O)OH,或者是一个五元杂环芳基,这些环可能被较低的烷基或环烷基取代;
n为0、1或2;
m为0、1或2;
或其药学上可接受的酸盐。化合物I显示出对GALA A &agr;5受体结合位点的高亲和力和选择性。